BENICAR
Pronunciation: awl-mi-SAR-tan


What it isAngiotensin II receptor blocker; hypertension.
Why this oneStrong pressure lowering is its appeal, but unlike several ARBs it lacks a separate heart-failure or kidney-disease indication.
What limits itSprue-like enteropathy with chronic diarrhea and weight loss is the distinctive risk, sometimes appearing years in. Hyperkalemia as for the class.
Animated chart of estimated U.S. prescriptions per year, RAAS inhibitors (1981–2026). Olmesartan enters in 2002 (estimated).
Principal riskHyperkalemia; sprue-like enteropathy
Legacy pregnancy categoryD
Defining liabilityHyperkalemia, kidney injury, fetal toxicity and increased lithium exposure.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Hypertension | Adults | 20 mg QD | 20-40 mg QD | 40 mg QD |
| Hypertension | Children ≥6 yr, 20 to <35 kg | 10 mg QD | 10-20 mg QD | 20 mg QD |
| Hypertension | Children ≥6 yr, ≥35 kg | 20 mg QD | 20-40 mg QD | 40 mg QD |
Titration May increase after 2 weeks if further BP reduction needed
Renal Undefined
Hepatic Undefined
Doses above 40 mg have no greater effect; twice-daily offers no advantage over same total daily dose
Available strengths
Pregnancy Can cause fetal harm; discontinue as soon as pregnancy is detected
Lactation No human data; decide whether to discontinue nursing or the drug
Generic entry2016
Open Olmesartan in the interactive console ↗

Open Olmesartan in the interactive console ↗